CorporateInformation.com
 
Company Search:
Advanced Search
 
Sponsored Links
 
 
 
 
 
 
 
Hubei Biocause Pharmaceutical Co., Ltd. Company Snapshot
Hubei Biocause Pharmaceutical Co., Ltd. operates in the Industrial organic chemicals sector. In addition to historical fundamental analyses, the complete report available to purchase compares Hubei Biocause Pharmaceutical Co., Ltd. with three other companies in this sector in China: Shanghai Huayi Group Corp Ltd (2017 sales of 43.73 billion Chinese Renmimbi [US$6.39 billion] of which 51% was Chemical Services), China Petroleum Engineering Corp (55.36 billion Chinese Renmimbi [US$8.09 billion] of which 40% was Oil and Gas Field Surface Engineering), and Zibo Qixiang Tengda Chemical Company Limited (22.23 billion Chinese Renmimbi [US$3.25 billion] of which 57% was Supply Chain).

Sales Analysis. Sales increased substantially in 2017: Hubei Biocause Pharmaceutical Co., Ltd. reported sales of 53.41 billion Chinese Renmimbi (US$7.80 billion) for the year ending December of 2017. This represents an increase of 214.3% versus 2016, when the company's sales were 16.99 billion Chinese Renmimbi. Sales of Insurance saw an increase that was more than double the company's growth rate: sales were up 496.1% in 2017, from 8.87 billion Chinese Renmimbi to 52.89 billion Chinese Renmimbi. Not all segments of Hubei Biocause Pharmaceutical Co., Ltd. experienced an increase in sales in 2017: sales of Chemical Manufacturing fell 58.1% to 149.13 million Chinese Renmimbi. (However, this segment's sales were only a very small portion of the company's overall sales). Hubei Biocause Pharmaceutical Co., Ltd. also experienced decreases in sales in Pharmaceutical Manufacturing (down 23.0% to 370.51 million Chinese Renmimbi) .
   
   
 
Company ReportsSubscriptions
 
Looking For More?
Purchace an In-Depth Report
Hubei Biocause Pharmaceutical Co., Ltd.
  Stock Performance Chart for Hubei Biocause Pharmaceutical Co., Ltd.
 
  Stock Data: Recent Stock Performance:
  Current Price (8/10/2018): 6.49
(Figures in Chinese Renmimbi)
1 Week 0.9%   13 Weeks -3.3%  
4 Weeks -16.7%   52 Weeks -27.1%  
 
Hubei Biocause Pharmaceutical Co., Ltd. Key Data:
  Ticker: 000627 Country: China
  Exchanges: SZN Major Industry: Materials
    Sub Industry: Chemicals & Allied Products
  2017 Sales 53,407,662,058
(Year Ending Jan 2018).
Employees: 5,099
  Currency: Chinese Renmimbi Market Cap: 32,064,683,281
  Fiscal Yr Ends: December Shares Outstanding: 4,940,629,165
  Share Type: A Gu Closely Held Shares: 3,277,015,260
 
 
Sponsored Links
 
 
 
 
Feedback | Terms and Conditions | Privacy Policy | Site Index
 
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.